BMS on the prowl for deals
Fiercebiotech (Free subscription) | 10/23/2009
During Bristol-Myers Squibb's Q3 earnings call yesterday, CEO Jim Cornelius ( photo ) said the company has over $1.3 billion in its coffers to finance more deals with small drug developers. That's despite it's recent buyout of Medarex for $2.1 billion. The company will "continue to aggressively pursue acquisitions, licensing deals and other partnerships," promised Cornelius....



